Bitter Taste Receptors in Oropharynx Cancer

Status Recruiting

Clinical Trial Summary

The aim of this work is to investigate the expression of the bitter taste receptors in p16-positive and negative oropharyngeal carcinomas (in comparison to healthy, local tissue).

Clinical Trial Description

Goal setting The aim of this work is to investigate the expression of the bitter taste receptors in p16-positive and negative oropharyngeal carcinomas (in comparison to healthy, local tissue). The hypothesis is that oropharyngeal carcinomas express TAS2Rs and that their stimulation can induce apoptosis. The lower expression of certain TAS2Rs in the tumor cells could represent protection from apoptosis by stimulation with the bitter ligands. Alternatively, it could polymorphisms of the bitter taste receptors, which can influence their function independently of the expression. In order to address the question of general bitter sensitivity in more detail, the investigators are planning to carry out a bitter taste test on the test subjects. methodology As this is a pilot study, the investigators limit the number of subjects to 10 patients with p-16 positive and negative oropharyngeal squamous cell carcinoma and 10 patients with acute recurrent tonsillitis or other benign pathology in pharynx. The expression analysis is carried out using qPCR and possibly immunohistochemical methods. Taste strips are used for the taste tests. Cognitive interest The results of this study will provide important insight into the pathophysiology of oropharyngeal cancers and possibly all TAS2R-expressing cancers. In addition, this and further studies can create a theoretical basis for new therapeutic methods for this group of diseases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05211427
Study type	Interventional
Source	Technische Universität Dresden
Contact
Status	Recruiting
Phase	N/A
Start date	March 23, 2021
Completion date	July 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04444869` - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer	Phase 2
Completed	`NCT00158678` - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC	Phase 3
Completed	`NCT04567082` - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Recruiting	`NCT06016699` - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn	`NCT04001413` - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	Phase 2
Completed	`NCT03435471` - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer	N/A
Completed	`NCT05055206` - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers	N/A
Recruiting	`NCT04359199` - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting	`NCT05793151` - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy	N/A
Active, not recruiting	`NCT02908477` - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer	Phase 3
Active, not recruiting	`NCT00232960` - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC	N/A
Completed	`NCT05698667` - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer	N/A
Recruiting	`NCT05757817` - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae	N/A
Active, not recruiting	`NCT02586207` - Pembrolizumab in Combination With CRT for LA-SCCHN	Phase 1
Completed	`NCT01108042` - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer	Phase 1/Phase 2
Completed	`NCT03342378` - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting	`NCT03416153` - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer	Phase 2
Terminated	`NCT01066741` - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer	Phase 3
Completed	`NCT03418792` - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx	N/A
Recruiting	`NCT06088381` - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)	Phase 2